(S)-叔丁基2-羟基丙基氨基甲酸酯 | 167938-56-9

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-叔丁基2-羟基丙基氨基甲酸酯
• 中文别名: (S)-1-(Boc-氨基)-2-丙醇；N-叔丁氧羰基-(S)-1-氨基-2-丙醇；(S)-1-(BOC-氨基)-2-丙醇；(S)-叔丁基(2-羟基丙基)氨基甲酸酯
• 英文名称: tert-butyl [(2S)-2-hydroxypropyl]carbamate
• 英文别名: tert-butyl (S)-(2-hydroxypropyl)carbamate；tert-butyl N-[(2S)-2-hydroxypropyl]carbamate；((S)-2-hydroxypropyl)carbamic acid tert-butyl ester；(S)-tert-butyl (2-hydroxypropyl)carbamate；N-Boc-(S)-1-amino-2-propanol
• CAS: 167938-56-9
• 化学式: C₈H₁₇NO₃
• mdl: MFCD02093569
• 分子量: 175.228
• InChiKey: YNJCFDAODGKHAV-LURJTMIESA-N

物化性质

• 沸点：
  276.4±23.0 °C(Predicted)
• 密度：
  1.025±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2924199090
• 储存条件：
  应存于室温、避光环境中，并在惰性气体氛围下保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
N-Boc-(S)-1-amino-2-propanol
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
N-Boc-(S)-1-amino-2-propanol
Ingredient name:
CAS number: 167938-56-9

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H17NO3
Molecular weight: 175.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-叔丁基2-羟基丙基氨基甲酸酯 在 2,4,6-Triisopropylthiophenol 、 Ir[dF(CF₃)ppy]₂(5,5'-dCF₃bpy)PF₆ 、 tetrabutylphosphonium diphenyl phosphate 作用下， 反应 24.0h， 以75%的产率得到甲基-氨基甲酸叔丁酯
  参考文献：
  名称：

  用于光驱动、失衡异构化的氧化还原策略及其在催化 C-C 键裂解反应中的应用

  摘要：

  我们报告了光驱动的环状脂肪醇异构化为线性羰基化合物的通用协议。这些反应通过醇 OH 键的质子耦合电子转移活化进行，随后生成的烷氧基自由基中间体的 CC β 断裂。在许多情况下，这些氧化还原中性异构化与显着的能量梯度相反，产生的产品热力学稳定性低于起始材料。提出了一种机制来合理化这种不平衡行为，该机制可以作为设计由激发态氧化还原事件驱动的其他逆热力学转换的模型。

  DOI：

  10.1021/jacs.8b12552
• 作为产物：
  描述：

  (2-氧代丙基)氨基甲酸叔丁酯 在 [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ 、 (1R,2R)-(-)-N-(对甲基苯磺酰基)-1,2-二苯基乙二胺 甲酸 、 三乙胺 作用下， 反应 24.0h， 以87.3%的产率得到(S)-叔丁基2-羟基丙基氨基甲酸酯
  参考文献：
  名称：

  Enantioselective synthesis of β-hydroxy amines and aziridines using asymmetric transfer hydrogenation of α-amino ketones

  摘要：

  α-氨基酮的对映选择性转移氢化是一种有效的方法，用于手性合成β-羟基胺和氮丙啶。

  DOI：

  10.1039/b102895m

文献信息

• [EN] HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONTENANT UN COEUR PYRROLOPYRIDINE OU BENZIMIDAZOLE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2011071725A1

  公开（公告）日：2011-06-16

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)化合物及其药用盐，其中R1、R2、R3、R4、R5和n的定义如本文中所述。本发明还涉及包含这些化合物的药物组合物、使用这些化合物治疗各种疾病和失调的方法、制备这些化合物的方法以及在这些过程中有用的中间体。
• [EN] 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS<br/>[FR] COMPOSÉS 6,7-DIHYDROPYRAZOLO[1,5-A] PYRAZIN-4(5H)-ONE ET LEUR UTILISATION COMME MODULATEURS ALLOSTÉRIQUES NÉGATIFS DES RÉCEPTEURS MGLUR2
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2016016395A1

  公开（公告）日：2016-02-04

  The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

  本发明涉及新型的6,7-二氢吡唑[1,5-a]吡嗪-4(5H)-酮衍生物，作为代谢型谷氨酸受体2型("mGluR2")的负变构调节剂(NAMs)。该发明还涉及包含这些化合物的药物组合物，制备这些化合物和组合物的方法，以及使用这些化合物和组合物预防或治疗涉及代谢型受体mGluR2亚型的疾病。
• [EN] HYDROXAMATE COMPOUNDS AS ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR<br/>[FR] COMPOSÉS HYDROXAMATE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR A2A DE L'ADÉNOSINE
  申请人：ADORX THERAPEUTICS LTD

  公开号：WO2020260857A1

  公开（公告）日：2020-12-30

  The present invention relates to compounds of formula I shown below: (I) wherein R1, R2 and R3 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine A2a receptor activity is implicated, such as, for example, cancer.

  本发明涉及下面所示的式I的化合物：(I)，其中R1、R2和R3在申请中各自定义。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗腺苷A2a受体活性参与的疾病或症状中的用途，例如癌症。
• Hydrogen Bonding and Alcohol Effects in Asymmetric Hypervalent Iodine Catalysis: Enantioselective Oxidative Dearomatization of Phenols
  作者：Muhammet Uyanik、Takeshi Yasui、Kazuaki Ishihara

  DOI：10.1002/anie.201303559

  日期：2013.8.26

  Iodine chooses: A conformationally flexible C2‐symmetric organoiodine(III) catalyst for the highly enantioselective catalytic oxidative dearomatization of phenols has been developed. Catalysis is controlled by intramolecular hydrogen‐bonding interactions and additional achiral alcohols.

  碘的选择：已开发出一种构象灵活的C 2对称有机碘（III）催化剂，用于酚的高对映选择性催化氧化脱芳香化反应。催化作用是通过分子内氢键相互作用和其他非手性醇来控制的。
• [EN] 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES<br/>[FR] 3-AMINO-1,5,6,7-TÉTRAHYDRO-4H-INDOL-4-ONES
  申请人：BAYER PHARMA AG

  公开号：WO2016202755A1

  公开（公告）日：2016-12-22

  Compounds of formula (I) as described hereinprocesses for their production and their use as anti-cancer agents.

  本文描述的式(I)化合物，其生产方法及其作为抗癌药物的用途。